NewEdge Advisors’s Integra LifeSciences IART Stock Holding History

NewEdge Advisors’s Portfolio IART Stock Details IART Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-40	Closed	-$491	–	4170
2025 Q2	$491	Hold	40	–	–	﹤0.01%	3804
2025 Q1	$880	Hold	40	–	–	﹤0.01%	3648
2024 Q4	$907	Hold	40	–	–	﹤0.01%	3578
2024 Q3	$727	Hold	40	–	–	﹤0.01%	3563
2024 Q2	$1.17K	Sell	40 -6	-13%	-$178	﹤0.01%	3437
2024 Q1	$1.63K	Sell	46 -12	-21%	-$480	﹤0.01%	3414
2023 Q4	$2.53K	Buy	58 +32	+123%	+$1.26K	﹤0.01%	3298
2023 Q3	$993	Sell	26 -24	-48%	-$1.01K	﹤0.01%	3173
2023 Q2	$2.06K	Sell	50 -4,619	-99%	-$222K	﹤0.01%	3088
2023 Q1	$268K	Buy	4,669 +4,502	+2,696%	+$254K	﹤0.01%	1415
2022 Q4	$3.82K	Buy	+167	New	+$8.5K	﹤0.01%	2675

Other funds holding IART

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PCMI

Paradigm Capital Management Inc Albany, New York $2.61B AUM 78.58% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

NewEdge Advisors's IART Position: Q3 2025 in Review

NewEdge Advisors sold out of Integra LifeSciences (IART) in Q3 2025, closing a stake of 40 shares — an estimated $491 sold.

NewEdge Advisors first reported a position in IART in Q4 2022 and held it in 11 quarters. The position peaked at $268K in Q1 2023. 207 funds tracked by Wall St. Rank hold IART as of Q3 2025.

NewEdge Advisors reported no remaining Integra LifeSciences position as of Q3 2025 after selling out during the quarter.
NewEdge Advisors sold 40 Integra LifeSciences shares in Q3 2025, an estimated $491.
NewEdge Advisors first reported a position in Integra LifeSciences in Q4 2022 and held it in 11 quarters.
NewEdge Advisors's Integra LifeSciences position peaked at $268K in Q1 2023.
207 funds tracked by Wall St. Rank held Integra LifeSciences as of Q3 2025.

Based on NewEdge Advisors's 13F filing for Q3 2025, filed 17 Nov 2025.